In the time between approval for use in children and the time it takes to do one or more trials and gain approval if those trials prove it to be worthwhile for adults there will be a large off-label market.
There are all those adults with aGVHD or Chronic GVHD etc in the US who's healthcare professionals might suggest trying Remestemcel-L as an off-label solution worth trying, in the absence of anything else working for them, that is they are steroid refractory, or have issues with long term use of steroids.
That additional income to Mesoblast needs to be factored in if you are going to start assigning values, for a more complete picture, off-label use is supposed to be a bigger market than paediatric use, and my guess is it will continue to be after adult GVHD approval if that happens.
In the time between approval for use in children and the time it...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |